Business
Fundraising, Posting of Circular & Notice of GM
Oxford BioDynamics PLC announced a conditional fundraising to raise £7 million before fees. This will be achieved through a placing of 2,301,666,661 new ordinary shares and direct subscriptions for 31,666,665 new ordinary shares, both at an issue price of £0.003 per share. The new ordinary shares will represent approximately 54.4% of the company's enlarged ordinary share capital. The fundraising is conditional on shareholder approval at a General Meeting on November 7, 2025, and admission of the new ordinary shares to trading on AIM. The raised capital will support the company's operations as test sales increase and while it pursues additional funding opportunities. Disclaimer*
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF OXFORD BIODYNAMICS PLC IN ANY JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED (\"MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, SUCH INFORMATION WILL NO LONGER CONSTITUTE INSIDE INFORMATION.\nOXFORD BIODYNAMICS PLC\nPlacing and Subscriptions to raise £7,000,000\nPosting of Circular to Shareholders\nand\nNotice of General Meeting\nOxford, UK - 22 October 2025 - Oxford BioDynamics Plc (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that it has conditionally raised in aggregate £7 million (before fees and expenses) pursuant to a placing of 2,301,666,661 new Ordinary Shares of £0.001 each (the \"Placing Shares\") with new and existing institutional and other investors (the \"Placing\") and through direct subscriptions for 31,666,665 new Ordinary Shares of £0.001 each (the \"Subscription Shares\" and, together with the Placing Shares, the \"New Ordinary Shares\") (the \"Subscriptions\"). The Placing and the Subscriptions (together the \"Fundraising\") are being carried out at an issue price of £0.003 per Ordinary Share of £0.001 each (the \"Issue Price\").\n \nThe Fundraising is conditional upon, amongst other things, the approval by Shareholders of resolutions to be propo...